Repligen reports Q3 2026 financial results and updates FY26 guidance
Repligen generated $209.3 million in Q3 2026 revenue and raised full-year revenue guidance to $844-$852 million. The company also closed the acquisition of BioLife Solutions to accelerate growth in the cell therapy market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed